iOnctura Receives €17.5M Funding from the EIC Accelerator
- iOnctura BV, an Amsterdam, Netherlands-based clinical-stage biotech developing cancer therapies, raised €17.5M in funding
- The company intends to use the funds to advance its clinical program for IOA-289, an autotaxin inhibitor for the treatment of cancer
- The company is a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways
- The company has progressed two therapeutic candidates into mid-stage clinical development
- On 8 December 2022, the platform announced the first patient was dosed in a Phase Ib clinical trial of IOA-289 in metastatic pancreatic cancer
